{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:00:07Z","timestamp":1790092807126,"version":"4.0.1"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000266","name":"RCUK | Engineering and Physical Sciences Research Council","doi-asserted-by":"publisher","award":["EP\/Y035216\/1"],"award-info":[{"award-number":["EP\/Y035216\/1"]}],"id":[{"id":"10.13039\/501100000266","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Some schizophrenia patients share characteristics with behavioral variant frontotemporal dementia (bvFTD) including gray matter volume (GMV) similarities, suggesting overlapping brain mechanisms that may contribute to disease heterogeneity in schizophrenia. However, it is not yet understood whether schizophrenia patients with a bvFTD-like GMV signature also show additional features of bvFTD. Seventy-six patients with schizophrenia (mean age 31.2 years; 71% male) from a previous clinical trial (NCT04038957) underwent structural magnetic resonance imaging (MRI) to measure GMV. Healthy controls (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200979) were used for age-related dynamic standardisation. Subsets of patients also completed [\u00b9\u2078F]-DOPA positron emission tomography (PET;\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200940) for striatal dopamine synthesis, neuromelanin-sensitive MRI (NM-MRI;\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200968) for midbrain dopaminergic integrity, and quantitative susceptibility mapping (QSM;\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200969) for brain iron accumulation. A previously validated machine-learning\u2013based GMV classifier quantified bvFTD-like pattern expression in each schizophrenia patient. Associations with neurochemical, clinical, and medication measures were examined using correlation analyses. Higher bvFTD scores were associated with lower striatal dopamine synthesis capacity (\n                    <jats:italic>r<\/jats:italic>\n                    \u2009=\u2009\u20130.343,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.032) and higher striatal QSM values (\n                    <jats:italic>r<\/jats:italic>\n                    \u2009=\u20090.282,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.020), but showed no significant association with QSM or NM-MRI values in the dopaminergic midbrain (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.903 and\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.102, respectively). No significant associations were found with negative symptom severity or with medication. Schizophrenia patients expressing a stronger bvFTD-like GMV pattern show lower striatal dopamine synthesis and elevated striatal iron, both hallmark features of bvFTD. This contrasts with the hyperdopaminergic model of schizophrenia and suggests distinct, potentially neurodegenerative mechanisms.\n                  <\/jats:p>","DOI":"10.1038\/s41386-026-02426-x","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T04:49:17Z","timestamp":1777092557000},"page":"2074-2082","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A frontotemporal dementia\u2013like phenotype in schizophrenia: links to striatal dopamine and iron accumulation"],"prefix":"10.1038","volume":"51","author":[{"given":"Xuanhan","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1249-5975","authenticated-orcid":false,"given":"Linda","family":"Bryant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Mena Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2928-1972","authenticated-orcid":false,"given":"Oliver","family":"Howes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Sedlacik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Veronese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7977-1083","authenticated-orcid":false,"given":"Matthias L.","family":"Schroeter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9642-3080","authenticated-orcid":false,"given":"Paris Alexandros","family":"Lalousis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Koutsouleris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1624-490X","authenticated-orcid":false,"given":"Luke","family":"Vano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8951-1467","authenticated-orcid":false,"given":"Fiona","family":"Coutts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"key":"2426_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.1017399","volume":"13","author":"K Fang","year":"2022","unstructured":"Fang K, Wen B, Niu L, Wan B, Zhang W. Higher brain structural heterogeneity in schizophrenia. Front Psychiatry. 2022;13:1017399.","journal-title":"Front Psychiatry"},{"key":"2426_CR2","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1001\/jamapsychiatry.2019.0257","volume":"76","author":"D Aln\u00e6s","year":"2019","unstructured":"Aln\u00e6s D, Kaufmann T, van der Meer D, C\u00f3rdova-Palomera A, Rokicki J, Moberget T, et al. Brain heterogeneity in schizophrenia and its association with polygenic risk. JAMA Psychiatry. 2019;76:739\u201348.","journal-title":"JAMA Psychiatry"},{"key":"2426_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.schres.2013.05.028","volume":"150","author":"R Tandon","year":"2013","unstructured":"Tandon R, Gaebel W, Barch DM, Bustillo J, Gur RE, Heckers S, et al. Definition and description of schizophrenia in the DSM-5. Schizophr Res. 2013;150:3\u201310.","journal-title":"Schizophr Res"},{"key":"2426_CR4","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1001\/archpsyc.1987.01800190080012","volume":"44","author":"DR Weinberger","year":"1987","unstructured":"Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry. 1987;44:660\u20139.","journal-title":"Arch Gen Psychiatry"},{"key":"2426_CR5","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3390\/biom15050615","volume":"15","author":"L Vellucci","year":"2025","unstructured":"Vellucci L, Mazza B, Barone A, Nasti A, De Simone G, Iasevoli F, et al. The role of astrocytes in the molecular pathophysiology of schizophrenia: between neurodevelopment and neurodegeneration. Biomolecules. 2025;15:615.","journal-title":"Biomolecules"},{"key":"2426_CR6","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.schres.2022.03.004","volume":"243","author":"WS Stone","year":"2022","unstructured":"Stone WS, Phillips MR, Yang LH, Kegeles LS, Susser ES, Lieberman JA. Neurodegenerative model of schizophrenia: growing evidence to support a revisit. Schizophr Res. 2022;243:154\u201362.","journal-title":"Schizophr Res"},{"key":"2426_CR7","doi-asserted-by":"crossref","unstructured":"Jarskog LF, Gilmore JH, Lieberman JA. Neurodegenerative models of schizophrenia. In: Neurodevelopment and Schizophrenia. New York, NY, US: Cambridge University Press; 2004. pp. 373\u201389.","DOI":"10.1017\/CBO9780511735103.022"},{"key":"2426_CR8","unstructured":"Kraepelin E Dementia praecox and paraphrenia. In: Textbook of Psychiatry, 8th edn. Livingston: Edinburgh; 1919."},{"key":"2426_CR9","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1177\/0957154X13501454","volume":"24","author":"K McNally","year":"2013","unstructured":"McNally K. Dementia praecox revisited. Hist Psychiatry. 2013;24:507\u20139.","journal-title":"Hist Psychiatry"},{"key":"2426_CR10","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1093\/brain\/awaa018","volume":"143","author":"S Ducharme","year":"2020","unstructured":"Ducharme S, Dols A, Laforce R, Devenney E, Kumfor F, van den Stock J, et al. Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders. Brain J Neurol. 2020;143:1632\u201350.","journal-title":"Brain J Neurol"},{"key":"2426_CR11","doi-asserted-by":"publisher","first-page":"12987","DOI":"10.3390\/ijms252312987","volume":"25","author":"S Ferretti","year":"2024","unstructured":"Ferretti S, Zanella I. The underestimated role of iron in frontotemporal dementia: a narrative review. Int J Mol Sci. 2024;25:12987.","journal-title":"Int J Mol Sci"},{"key":"2426_CR12","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1016\/S0140-6736(15)00461-4","volume":"386","author":"J Bang","year":"2015","unstructured":"Bang J, Spina S, Miller BL. Frontotemporal dementia. Lancet. 2015;386:1672\u201382.","journal-title":"Lancet"},{"key":"2426_CR13","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1093\/brain\/awaf061","volume":"148","author":"MA Rouse","year":"2025","unstructured":"Rouse MA, Husain M, Garrard P, Patterson K, Rowe JB, Lambon Ralph MA. Behavioural changes in frontotemporal dementia and their cognitive and neuroanatomical correlates. Brain J Neurol. 2025;148:2730\u201345.","journal-title":"Brain J Neurol"},{"key":"2426_CR14","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1192\/bjp.bp.108.057034","volume":"194","author":"D Velakoulis","year":"2009","unstructured":"Velakoulis D, Walterfang M, Mocellin R, Pantelis C, McLean C. Frontotemporal dementia presenting as schizophrenia-like psychosis in young people: clinicopathological series and review of cases. Br J Psychiatry J Ment Sci. 2009;194:298\u2013305.","journal-title":"Br J Psychiatry J Ment Sci"},{"key":"2426_CR15","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.neuron.2011.09.010","volume":"72","author":"AE Renton","year":"2011","unstructured":"Renton AE, Majounie E, Waite A, Sim\u00f3n-S\u00e1nchez J, Rollinson S, Gibbs JR, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257\u201368.","journal-title":"Neuron"},{"key":"2426_CR16","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.biopsych.2022.05.028","volume":"93","author":"H Ulugut","year":"2023","unstructured":"Ulugut H, Trieu C, Groot C, Van \u2019T Hooft JJ, Tijms BM, Scheltens P, et al. Overlap of neuroanatomical involvement in frontotemporal dementia and primary psychiatric disorders: a meta-analysis. Biol Psychiatry. 2023;93:820\u20138.","journal-title":"Biol Psychiatry"},{"key":"2426_CR17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cortex.2014.02.022","volume":"57","author":"ML Schroeter","year":"2014","unstructured":"Schroeter ML, Laird AR, Chwiesko C, Deuschl C, Schneider E, Bzdok D, et al. Conceptualizing neuropsychiatric diseases with multimodal data-driven meta-analyses - the case of behavioral variant frontotemporal dementia. Cortex J Devoted Study Nerv Syst Behav. 2014;57:22\u201337.","journal-title":"Cortex J Devoted Study Nerv Syst Behav"},{"key":"2426_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2024.1356975","volume":"15","author":"C Chaves","year":"2024","unstructured":"Chaves C, Dursun SM, Tusconi M, Hallak JEC. Neuroinflammation and schizophrenia - is there a link? Front Psychiatry. 2024;15:1356975.","journal-title":"Front Psychiatry"},{"key":"2426_CR19","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00415-025-13268-w","volume":"272","author":"JH Hou","year":"2025","unstructured":"Hou JH, Chu M, Chen ZY, Jiang DM, Chen YF, Yue AL, et al. Interaction of metabolic and inflammatory dysregulation on central degeneration and cognitive function in behavioral variant Frontotemporal dementia. J Neurol. 2025;272:533.","journal-title":"J Neurol"},{"key":"2426_CR20","doi-asserted-by":"publisher","first-page":"478","DOI":"10.9758\/cpn.22.991","volume":"21","author":"WH Chang","year":"2023","unstructured":"Chang WH, Su CC, Chen KC, Hsiao YY, Chen PS, Yang YK. Which severe mental illnesses most increase the risk of developing dementia? Comparing the risk of dementia in patients with schizophrenia, major depressive disorder and bipolar disorder. Clin Psychopharmacol Neurosci. 2023;21:478\u201387.","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"2426_CR21","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1001\/jamapsychiatry.2022.2075","volume":"79","author":"N Koutsouleris","year":"2022","unstructured":"Koutsouleris N, Pantelis C, Velakoulis D, McGuire P, Dwyer DB, Urquijo-Castro MF, et al. Exploring links between psychosis and frontotemporal dementia using multimodal machine learning: dementia praecox revisited. JAMA Psychiatry. 2022;79:907.","journal-title":"JAMA Psychiatry"},{"key":"2426_CR22","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1212\/WNL.58.10.1489","volume":"58","author":"JO Rinne","year":"2002","unstructured":"Rinne JO, Laine M, Kaasinen V, Norvasuo-Heil\u00e4 MK, N\u00e5gren K, Helenius H. Striatal dopamine transporter and extrapyramidal symptoms in frontotemporal dementia. Neurology. 2002;58:1489\u201393.","journal-title":"Neurology"},{"key":"2426_CR23","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1093\/brain\/awx327","volume":"141","author":"AG Murley","year":"2018","unstructured":"Murley AG, Rowe JB. Neurotransmitter deficits from frontotemporal lobar degeneration. Brain. 2018;141:1263\u201385.","journal-title":"Brain"},{"key":"2426_CR24","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1001\/archgenpsychiatry.2012.169","volume":"69","author":"OD Howes","year":"2012","unstructured":"Howes OD, Kambeitz J, Kim E, Stahl D, Slifstein M, Abi-Dargham A, et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry. 2012;69:776\u201386.","journal-title":"Arch Gen Psychiatry"},{"key":"2426_CR25","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1176\/appi.ajp.2012.12010144","volume":"169","author":"A Demjaha","year":"2012","unstructured":"Demjaha A, Murray RM, McGuire PK, Kapur S, Howes OD. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. Am J Psychiatry. 2012;169:1203\u201310.","journal-title":"Am J Psychiatry"},{"key":"2426_CR26","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/npp.2016.258","volume":"42","author":"E Kim","year":"2017","unstructured":"Kim E, Howes OD, Veronese M, Beck K, Seo S, Park JW, et al. Presynaptic dopamine capacity in patients with treatment-resistant schizophrenia taking clozapine: an [18F]DOPA PET study. Neuropsychopharmacol Publ Am Coll Neuropsychopharmacol. 2017;42:941\u201350.","journal-title":"Neuropsychopharmacol Publ Am Coll Neuropsychopharmacol"},{"key":"2426_CR27","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.pneurobio.2015.09.012","volume":"155","author":"FA Zucca","year":"2017","unstructured":"Zucca FA, Segura-Aguilar J, Ferrari E, Mu\u00f1oz P, Paris I, Sulzer D, et al. Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson\u2019s disease. Prog Neurobiol. 2017;155:96\u2013119.","journal-title":"Prog Neurobiol"},{"key":"2426_CR28","doi-asserted-by":"crossref","unstructured":"Vano LJ, Sedlacik J, Carr RW, Bukala BR, Howes OD, McCutcheon RA. Grey matter iron and neuromelanin in psychosis: a systematic review and meta-analysis of MRI studies. medRxiv. 2026. https:\/\/www.medrxiv.org\/content\/10.64898\/2026.01.15.26344182v1.","DOI":"10.64898\/2026.01.15.26344182"},{"key":"2426_CR29","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1176\/appi.ajp.20220780","volume":"181","author":"M van der Pluijm","year":"2024","unstructured":"van der Pluijm M, Wengler K, Reijers PN, Cassidy CM, Tjong Tjin Joe K, de Peuter OR, et al. Neuromelanin-sensitive MRI as candidate marker for treatment resistance in first-episode schizophrenia. Am J Psychiatry. 2024;181:512\u20139.","journal-title":"Am J Psychiatry"},{"key":"2426_CR30","doi-asserted-by":"crossref","unstructured":"Duyn JH, Schenck J. Contributions to magnetic susceptibility of brain tissue. NMR Biomed. 2017;30:e3546.","DOI":"10.1002\/nbm.3546"},{"key":"2426_CR31","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.biopsych.2024.06.013","volume":"96","author":"LJ Vano","year":"2024","unstructured":"Vano LJ, McCutcheon RA, Rutigliano G, Kaar SJ, Finelli V, Nordio G, et al. Mesostriatal dopaminergic circuit dysfunction in schizophrenia: a multimodal neuromelanin-sensitive magnetic resonance imaging and [18F]-DOPA positron emission tomography study. Biol Psychiatry. 2024;96:674\u201383.","journal-title":"Biol Psychiatry"},{"key":"2426_CR32","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/s41380-025-03195-7","volume":"31","author":"LJ Vano","year":"2026","unstructured":"Vano LJ, McCutcheon RA, Sedlacik J, Rutigliano G, Kaar SJ, Finelli V, et al. The role of low subcortical iron, white matter myelin, and oligodendrocytes in schizophrenia: a quantitative susceptibility mapping and diffusion tensor imaging study. Mol Psychiatry. 2026;31:941\u201352.","journal-title":"Mol Psychiatry"},{"key":"2426_CR33","unstructured":"Howes OD, Vano LJ, Petty AE, Rutigliano G, Halff EF, Veronese M, et al. TAAR1 regulates presynaptic dopamine function: evidence from preclinical studies and a phase 1b trial in patients with schizophrenia. Biol Psychiatry. 2025;21;S0006-3223(25)01533-1."},{"key":"2426_CR34","unstructured":"First MB. Structured clinical interview for DSM-5 disorders: clinician version (SCID-5-CV). Arlington (VA): American Psychiatric Association Publishing; 2016."},{"key":"2426_CR35","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261\u201376.","journal-title":"Schizophr Bull"},{"key":"2426_CR36","doi-asserted-by":"publisher","first-page":"S90","DOI":"10.1093\/schbul\/sbv167","volume":"42","author":"S Leucht","year":"2016","unstructured":"Leucht S, Samara M, Heres S, Davis JM. Dose equivalents for antipsychotic drugs: the DDD method. Schizophr Bull. 2016;42:S90\u201394.","journal-title":"Schizophr Bull"},{"key":"2426_CR37","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1177\/02698811221122031","volume":"36","author":"I Angelescu","year":"2022","unstructured":"Angelescu I, Kaar SJ, Marques TR, Borgan F, Veronesse M, Sharman A, et al. The effect of AUT00206, a Kv3 potassium channel modulator, on dopamine synthesis capacity and the reliability of [18F]-FDOPA imaging in schizophrenia. J Psychopharmacol Oxf Engl. 2022;36:1061\u20139.","journal-title":"J Psychopharmacol Oxf Engl"},{"key":"2426_CR38","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.biopsych.2018.07.003","volume":"85","author":"S Jauhar","year":"2019","unstructured":"Jauhar S, Veronese M, Nour MM, Rogdaki M, Hathway P, Natesan S, et al. The effects of antipsychotic treatment on presynaptic dopamine synthesis capacity in first-episode psychosis: a positron emission tomography study. Biol Psychiatry. 2019;85:79\u201387.","journal-title":"Biol Psychiatry"},{"key":"2426_CR39","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1038\/jcbfm.1991.154","volume":"11","author":"WP Melega","year":"1991","unstructured":"Melega WP, Grafton ST, Huang SC, Satyamurthy N, Phelps ME, Barrio JR. L-6-[18F]fluoro-dopa metabolism in monkeys and humans: biochemical parameters for the formulation of tracer kinetic models with positron emission tomography. J Cereb Blood Flow Metab. 1991;11:890\u20137.","journal-title":"J Cereb Blood Flow Metab"},{"key":"2426_CR40","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.neuroimage.2011.10.025","volume":"62","author":"J Ashburner","year":"2012","unstructured":"Ashburner J. SPM: a history. Neuroimage. 2012;62:791\u2013800.","journal-title":"Neuroimage"},{"key":"2426_CR41","doi-asserted-by":"publisher","DOI":"10.1093\/gigascience\/giae049","volume":"13","author":"C Gaser","year":"2024","unstructured":"Gaser C, Dahnke R, Thompson PM, Kurth F, Luders E, The Alzheimer\u2019s Disease Neuroimaging Initiative null. CAT: a computational anatomy toolbox for the analysis of structural MRI data. GigaScience. 2024;13:giae049.","journal-title":"GigaScience"},{"key":"2426_CR42","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40708-021-00128-2","volume":"8","author":"AD Gilmore","year":"2021","unstructured":"Gilmore AD, Buser NJ, Hanson JL. Variations in structural MRI quality significantly impact commonly used measures of brain anatomy. Brain Inf. 2021;8:7.","journal-title":"Brain Inf"},{"key":"2426_CR43","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1016\/j.neuroimage.2010.09.025","volume":"54","author":"BB Avants","year":"2011","unstructured":"Avants BB, Tustison NJ, Song G, Cook PA, Klein A, Gee JC. A reproducible evaluation of ANTs similarity metric performance in brain image registration. NeuroImage. 2011;54:2033\u201344.","journal-title":"NeuroImage"},{"key":"2426_CR44","doi-asserted-by":"crossref","unstructured":"Salzman G, Kim J, Horga G, Wengler K. Standardized data acquisition for neuromelanin-sensitive magnetic resonance imaging of the substantia nigra. J Vis Exp. 2021;e62493.","DOI":"10.3791\/62493"},{"key":"2426_CR45","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/hbm.10062","volume":"17","author":"SM Smith","year":"2002","unstructured":"Smith SM. Fast robust automated brain extraction. Hum Brain Mapp. 2002;17:143\u201355.","journal-title":"Hum Brain Mapp"},{"key":"2426_CR46","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/mrm.24272","volume":"69","author":"T Liu","year":"2013","unstructured":"Liu T, Wisnieff C, Lou M, Chen W, Spincemaille P, Wang Y. Nonlinear formulation of the magnetic field to source relationship for robust quantitative susceptibility mapping. Magn Reson Med. 2013;69:467\u201376.","journal-title":"Magn Reson Med"},{"key":"2426_CR47","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1002\/nbm.1670","volume":"24","author":"T Liu","year":"2011","unstructured":"Liu T, Khalidov I, de Rochefort L, Spincemaille P, Liu J, Tsiouris AJ, et al. A novel background field removal method for MRI using projection onto dipole fields (PDF). NMR Biomed. 2011;24:1129\u201336.","journal-title":"NMR Biomed"},{"key":"2426_CR48","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1097\/01.WCB.0000048520.34839.1A","volume":"23","author":"D Martinez","year":"2003","unstructured":"Martinez D, Slifstein M, Broft A, Mawlawi O, Hwang DR, Huang Y, et al. Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab. 2003;23:285\u2013300.","journal-title":"J Cereb Blood Flow Metab"},{"key":"2426_CR49","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.neuroimage.2009.12.058","volume":"50","author":"A Egerton","year":"2010","unstructured":"Egerton A, Demjaha A, McGuire P, Mehta MA, Howes OD. The test-retest reliability of 18F-DOPA PET in assessing striatal and extrastriatal presynaptic dopaminergic function. NeuroImage. 2010;50:524\u201331.","journal-title":"NeuroImage"},{"key":"2426_CR50","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1097\/00004647-199911000-00003","volume":"19","author":"FE Turkheimer","year":"1999","unstructured":"Turkheimer FE, Brett M, Visvikis D, Cunningham VJ. Multiresolution analysis of emission tomography images in the wavelet domain. J Cereb Blood Flow Metab. 1999;19:1189\u2013208.","journal-title":"J Cereb Blood Flow Metab"},{"key":"2426_CR51","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1177\/0271678X231168687","volume":"43","author":"G Nordio","year":"2023","unstructured":"Nordio G, Easmin R, Giacomel A, Dipasquale O, Martins D, Williams S, et al. An automatic analysis framework for FDOPA PET neuroimaging. J Cereb Blood Flow Metab. 2023;43:1285\u2013300.","journal-title":"J Cereb Blood Flow Metab"},{"key":"2426_CR52","unstructured":"Koutsouleris N, Vetter NC, Wiegand P. NeuroMiner (version 1.2) [computer software]. 2023. https:\/\/github.com\/neurominer-git\/NeuroMiner_1.2"},{"key":"2426_CR53","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1176\/appi.ajp.20240512","volume":"182","author":"LJ Vano","year":"2025","unstructured":"Vano LJ, McCutcheon RA, Sedlacik J, Kaar SJ, Rutigliano G, Nordio G, et al. Reduced brain iron and striatal hyperdopaminergia in schizophrenia: a quantitative susceptibility mapping MRI and PET study. Am J Psychiatry. 2025;182:830\u20139.","journal-title":"Am J Psychiatry"},{"key":"2426_CR54","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/jmri.28530","volume":"58","author":"R Al Haddad","year":"2023","unstructured":"Al Haddad R, Chamoun M, Tardif CL, Guimond S, Horga G, Rosa-Neto P, et al. Normative values of neuromelanin-sensitive MRI signal in older adults obtained using a turbo spin echo sequence. J Magn Reson Imaging JMRI. 2023;58:294\u2013300.","journal-title":"J Magn Reson Imaging JMRI"},{"key":"2426_CR55","doi-asserted-by":"publisher","first-page":"4461","DOI":"10.1002\/alz.13863","volume":"20","author":"L H\u00fcper","year":"2024","unstructured":"H\u00fcper L, Steinacker P, Polyakova M, Mueller K, Godulla J, Herzig S, et al. Neurofilaments and progranulin are related to atrophy in frontotemporal lobar degeneration - a transdiagnostic study cross-validating atrophy and fluid biomarkers. Alzheimers Dement J Alzheimers Assoc. 2024;20:4461\u201375.","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"2426_CR56","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.tins.2018.12.004","volume":"42","author":"RA McCutcheon","year":"2019","unstructured":"McCutcheon RA, Abi-Dargham A, Howes OD. Schizophrenia, dopamine and the striatum: from biology to symptoms. Trends Neurosci. 2019;42:205\u201320.","journal-title":"Trends Neurosci"},{"key":"2426_CR57","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcaf284","volume":"7","author":"D Urso","year":"2025","unstructured":"Urso D, Anastasia A, Gnoni V, Giugno A, Vilella D, Vitulli A, et al. Striatal dopaminergic patterns and clinical features in frontotemporal dementia. Brain Commun. 2025;7:fcaf284.","journal-title":"Brain Commun"},{"key":"2426_CR58","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1007\/s00213-014-3523-4","volume":"231","author":"MAP Bloomfield","year":"2014","unstructured":"Bloomfield MAP, Morgan CJA, Kapur S, Curran HV, Howes OD. The link between dopamine function and apathy in cannabis users: an [18F]-DOPA PET imaging study. Psychopharmacology. 2014;231:2251\u20139.","journal-title":"Psychopharmacology"},{"key":"2426_CR59","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1093\/brain\/awr179","volume":"134","author":"K Rascovsky","year":"2011","unstructured":"Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain J Neurol. 2011;134:2456\u201377.","journal-title":"Brain J Neurol"},{"key":"2426_CR60","first-page":"728","volume":"18","author":"BT Peet","year":"2021","unstructured":"Peet BT, Spina S, Mundada N, La Joie R. Neuroimaging in frontotemporal dementia: heterogeneity and relationships with underlying neuropathology. Neurother J Am Soc Exp Neurother. 2021;18:728\u201352.","journal-title":"Neurother J Am Soc Exp Neurother"},{"key":"2426_CR61","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s13195-024-01596-4","volume":"16","author":"CM Weise","year":"2024","unstructured":"Weise CM, Engel A, Polyakova M, Wu Q, Mueller K, Herzig S, et al. Dissecting neural correlates of theory of mind and executive functions in behavioral variant frontotemporal dementia. Alzheimers Res Ther. 2024;16:237.","journal-title":"Alzheimers Res Ther"},{"key":"2426_CR62","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1093\/brain\/awr311","volume":"135","author":"ML Schroeter","year":"2012","unstructured":"Schroeter ML, Vogt B, Frisch S, Becker G, Barthel H, Mueller K, et al. Executive deficits are related to the inferior frontal junction in early dementia. Brain J Neurol. 2012;135:201\u201315.","journal-title":"Brain J Neurol"},{"key":"2426_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1192\/bjp.bp.113.138578","volume":"205","author":"OD Howes","year":"2014","unstructured":"Howes OD, Kapur S. A neurobiological hypothesis for the classification of schizophrenia: type A (hyperdopaminergic) and type B (normodopaminergic). Br J Psychiatry J Ment Sci. 2014;205:1\u20133.","journal-title":"Br J Psychiatry J Ment Sci"},{"key":"2426_CR64","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.biopsych.2022.07.017","volume":"93","author":"K Sabaroedin","year":"2023","unstructured":"Sabaroedin K, Tiego J, Fornito A. Circuit-based approaches to understanding corticostriatothalamic dysfunction across the psychosis continuum. Biol Psychiatry. 2023;93:113\u201324.","journal-title":"Biol Psychiatry"},{"key":"2426_CR65","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.neubiorev.2018.02.007","volume":"87","author":"PRA Heckman","year":"2018","unstructured":"Heckman PRA, Blokland A, Bollen EPP, Prickaerts J. Phosphodiesterase inhibition and modulation of corticostriatal and hippocampal circuits: clinical overview and translational considerations. Neurosci Biobehav Rev. 2018;87:233\u201354.","journal-title":"Neurosci Biobehav Rev"},{"key":"2426_CR66","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13195-022-01157-7","volume":"15","author":"L Liu","year":"2023","unstructured":"Liu L, Chu M, Nie B, Jiang D, Xie K, Cui Y, et al. Altered metabolic connectivity within the limbic cortico-striato-thalamo-cortical circuit in presymptomatic and symptomatic behavioral variant frontotemporal dementia. Alzheimers Res Ther. 2023;15:3.","journal-title":"Alzheimers Res Ther"},{"key":"2426_CR67","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.86085","volume":"13","author":"L Hahn","year":"2024","unstructured":"Hahn L, Eickhoff SB, Mueller K, Schilbach L, Barthel H, Fassbender K, et al. Resting-state alterations in behavioral variant frontotemporal dementia are related to the distribution of monoamine and GABA neurotransmitter systems. eLife. 2024;13:e86085.","journal-title":"eLife"},{"key":"2426_CR68","doi-asserted-by":"publisher","unstructured":"Ilchovska ZG, Lockwood J, Proctor E, Hosseini A, Ralph MAL, Jung J. The neural basis of frontotemporal dementia (FTD): insights from ALE meta-analyses of four FTD subtypes encompassing 8,057 patients. MedRxiv Prepr Serv Health Sci. 2025; https:\/\/doi.org\/10.1101\/2025.06.02.25328809.","DOI":"10.1101\/2025.06.02.25328809"},{"key":"2426_CR69","volume":"14","author":"A Kamalian","year":"2022","unstructured":"Kamalian A, Khodadadifar T, Saberi A, Masoudi M, Camilleri JA, Eickhoff CR, et al. Convergent regional brain abnormalities in behavioral variant frontotemporal dementia: a neuroimaging meta-analysis of 73 studies. Alzheimers Dement. 2022;14:e12318.","journal-title":"Alzheimers Dement"},{"key":"2426_CR70","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1111\/ene.12432","volume":"21","author":"JL De Reuck","year":"2014","unstructured":"De Reuck JL, Deramecourt V, Auger F, Durieux N, Cordonnier C, Devos D, et al. Iron deposits in post-mortem brains of patients with neurodegenerative and cerebrovascular diseases: a semi-quantitative 7.0 T magnetic resonance imaging study. Eur J Neurol. 2014;21:1026\u201331.","journal-title":"Eur J Neurol"},{"key":"2426_CR71","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s13760-017-0832-5","volume":"117","author":"J De Reuck","year":"2017","unstructured":"De Reuck J, Devos D, Moreau C, Auger F, Durieux N, Deramecourt V, et al. Topographic distribution of brain iron deposition and small cerebrovascular lesions in amyotrophic lateral sclerosis and in frontotemporal lobar degeneration: a post-mortem 7.0-tesla magnetic resonance imaging study with neuropathological correlates. Acta Neurol Belg. 2017;117:873\u20138.","journal-title":"Acta Neurol Belg"},{"key":"2426_CR72","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.3174\/ajnr.A5339","volume":"38","author":"R Sheelakumari","year":"2017","unstructured":"Sheelakumari R, Kesavadas C, Varghese T, Sreedharan RM, Thomas B, Verghese J, et al. Assessment of iron deposition in the brain in frontotemporal dementia and its correlation with behavioral traits. AJNR Am J Neuroradiol. 2017;38:1953\u20138.","journal-title":"AJNR Am J Neuroradiol"},{"key":"2426_CR73","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/S2215-0366(19)30520-6","volume":"7","author":"S Luza","year":"2020","unstructured":"Luza S, Opazo CM, Bousman CA, Pantelis C, Bush AI, Everall IP. The ubiquitin proteasome system and schizophrenia. Lancet Psychiatry. 2020;7:528\u201337.","journal-title":"Lancet Psychiatry"},{"key":"2426_CR74","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1038\/s41380-023-01979-3","volume":"28","author":"A Lotan","year":"2023","unstructured":"Lotan A, Luza S, Opazo CM, Ayton S, Lane DJR, Mancuso S, et al. Perturbed iron biology in the prefrontal cortex of people with schizophrenia. Mol Psychiatry. 2023;28:2058\u201370.","journal-title":"Mol Psychiatry"},{"key":"2426_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.957685","volume":"13","author":"T Zhu","year":"2022","unstructured":"Zhu T, Wang Z, Zhou C, Fang X, Huang C, Xie C, et al. Meta-analysis of structural and functional brain abnormalities in schizophrenia with persistent negative symptoms using activation likelihood estimation. Front Psychiatry. 2022;13:957685.","journal-title":"Front Psychiatry"},{"key":"2426_CR76","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1093\/brain\/awx101","volume":"140","author":"CJ Lansdall","year":"2017","unstructured":"Lansdall CJ, Coyle-Gilchrist ITS, Jones PS, V\u00e1zquez Rodr\u00edguez P, Wilcox A, Wehmann E, et al. Apathy and impulsivity in frontotemporal lobar degeneration syndromes. Brain J Neurol. 2017;140:1792\u2013807.","journal-title":"Brain J Neurol"},{"key":"2426_CR77","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1093\/schbul\/sbj053","volume":"32","author":"B Kirkpatrick","year":"2006","unstructured":"Kirkpatrick B, Fenton WS, Carpenter WT, Marder SR. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 2006;32:214\u20139.","journal-title":"Schizophr Bull"},{"key":"2426_CR78","doi-asserted-by":"publisher","first-page":"e1498","DOI":"10.1212\/WNL.0000000000006344","volume":"91","author":"EM Devenney","year":"2018","unstructured":"Devenney EM, Ahmed RM, Halliday G, Piguet O, Kiernan MC, Hodges JR. Psychiatric disorders in C9orf72 kindreds: study of 1,414 family members. Neurology. 2018;91:e1498\u2013507.","journal-title":"Neurology"},{"key":"2426_CR79","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2021.661447","volume":"15","author":"J Smeyers","year":"2021","unstructured":"Smeyers J, Banchi EG, Latouche M. C9ORF72: what it is, what it does, and why it matters. Front Cell Neurosci. 2021;15:661447.","journal-title":"Front Cell Neurosci"},{"key":"2426_CR80","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3390\/antiox10010061","volume":"10","author":"PJ Urrutia","year":"2021","unstructured":"Urrutia PJ, B\u00f3rquez DA, N\u00fa\u00f1ez MT. Inflaming the brain with iron. Antioxidants. 2021;10:61.","journal-title":"Antioxidants"},{"key":"2426_CR81","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1038\/s41374-019-0197-x","volume":"99","author":"KH Strang","year":"2019","unstructured":"Strang KH, Golde TE, Giasson BI. MAPT mutations, tauopathy, and mechanisms of neurodegeneration. Lab Investig J Tech Methods Pathol. 2019;99:912\u201328.","journal-title":"Lab Investig J Tech Methods Pathol"},{"key":"2426_CR82","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1007\/s00259-024-06637-6","volume":"51","author":"C Ferschmann","year":"2024","unstructured":"Ferschmann C, Messerschmidt K, Gn\u00f6rich J, Barthel H, Marek K, Palleis C, et al. Tau accumulation is associated with dopamine deficiency in vivo in four-repeat tauopathies. Eur J Nucl Med Mol Imaging. 2024;51:1909\u201322.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2426_CR83","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00702-006-0536-0","volume":"114","author":"YF Tai","year":"2007","unstructured":"Tai YF, Ahsan RL, de Y\u00e9benes JG, Pavese N, Brooks DJ, Piccini P. Characterization of dopaminergic dysfunction in familial progressive supranuclear palsy: an 18F-dopa PET study. J Neural Transm. 2007;114:337\u201340.","journal-title":"J Neural Transm"},{"key":"2426_CR84","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1007\/s00259-025-07600-9","volume":"53","author":"F Weih","year":"2026","unstructured":"Weih F, Rullmann M, Henssen D, Meyer PM, Jochimsen T, Schildan A, et al. Hybrid Tau-PET\/MRI study: quantitative susceptibility mapping in progressive supranuclear palsy and its correlation with Tau-PET. Eur J Nucl Med Mol Imaging. 2026;53:2099\u2013109.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2426_CR85","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2026.1764148","volume":"17","author":"S Hou","year":"2026","unstructured":"Hou S, Chen L, Chang L, Huo C. The relationship between total tau protein, phosphorylated tau protein, schizophrenia and bipolar disorder: a systematic review and meta-analysis. Front Psychiatry. 2026;17:1764148.","journal-title":"Front Psychiatry"},{"key":"2426_CR86","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/acn3.683","volume":"6","author":"WR Bevan-Jones","year":"2019","unstructured":"Bevan-Jones WR, Cope TE, Jones PS, Passamonti L, Hong YT, Fryer T, et al. In vivo evidence for pre-symptomatic neuroinflammation in a MAPT mutation carrier. Ann Clin Transl Neurol. 2019;6:373\u20138.","journal-title":"Ann Clin Transl Neurol"},{"key":"2426_CR87","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1192\/bjp.bp.109.068981","volume":"197","author":"D Schoder","year":"2010","unstructured":"Schoder D, Hannequin D, Martinaud O, Opolczynski G, Guyant-Mar\u00e9chal L, Le Ber I, et al. Morbid risk for schizophrenia in first-degree relatives of people with frontotemporal dementia. Br J Psychiatry J Ment Sci. 2010;197:28\u201335.","journal-title":"Br J Psychiatry J Ment Sci"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41386-026-02426-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-026-02426-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-026-02426-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:04:12Z","timestamp":1790089452000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-026-02426-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":87,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2426"],"URL":"https:\/\/doi.org\/10.1038\/s41386-026-02426-x","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]},"assertion":[{"value":"26 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"OH has received investigator-initiated research funding from and\/or participated in advisory\/speaker meetings organized by Angelini, Autifony, Biogen, Boehringer-Ingelheim, Bristol-Myer Squibb, Eli Lilly, Heptares, Global Medical Education, Invicro, Karuna, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Teva, Recordati, Roche, and Viatris\/Mylan. OH and Veronese have a patent for the use of dopaminergic imaging (REF: WO\/2021\/111116). The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}